Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

It has been another busy week for Australia's top brokers. This has led to the release of a large number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

Smiling couple looking at a phone at a bargain opportunity.

Image source: Getty Images

Breville Group Ltd (ASX: BRG)

According to a note out of Goldman Sachs, its analysts have reiterated their buy rating and $24.50 price target on this appliance manufacturer's shares. This follows the release of the quarterly results of De Longhi. Breville's rival had a strong quarter and upgraded its full-year earnings guidance. Goldman feels this is further evidence of resilience of coffee category and bodes well for Breville's own performance. The Breville share price is trading at $23.30 today.

Qantas Airways Limited (ASX: QAN)

A note out of Macquarie reveals that its analysts have retained their outperform rating on this airline operator's shares with a reduced price target of $7. Macquarie highlights that travel demand remains resilient despite the tough economic backdrop. In light of this, it believes Qantas is well-positioned to generate strong earnings in the near term. The Qantas share price is fetching $5.26 this afternoon.

Xero Limited (ASX: XRO)

Analysts at Citi have retained their buy rating and $135.50 price target on this cloud accounting platform provider's shares. While the broker was a touch disappointed with Xero's half-year update and notes that it didn't deliver the earnings beat the market was expecting, it believes the share price reaction was overdone. As a result, Citi believes now is the time to snap up shares. The Xero share price is trading at $98.61 on Friday.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Macquarie Group, and Xero. The Motley Fool Australia has positions in and has recommended Macquarie Group and Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

woman on phone
Broker Notes

With $2.4 billion in FY26 profits, are Telstra shares a good buy today?

A leading expert delivers his outlook for Telstra shares.

Read more »

Woman looking at her computer and pondering something.
Broker Notes

Barrenjoey tips this ASX financial stock to rise 73%

A new deal has impressed the analysts.

Read more »

Sell written several times on board.
Broker Notes

Sell alert! Expert calls time on Corporate Travel and CBA shares

A leading expert expects CBA and Corporate Travel shares to face significant headwinds.

Read more »

Red buy button on an Apple keyboard with a finger on it.
Broker Notes

Expert names Woodside and CSL shares as top buys today

A leading expert says now is the time to buy CSL and Woodside shares. But why?

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Buy, hold, sell: Telix Pharmaceuticals, Qualitas, Greatland Resources shares

Here's what Mark Gardner from MPC Markets thinks of these three ASX shares.

Read more »

Two brokers analysing the share price with the woman pointing at the screen and man talking on a phone.
Broker Notes

Buy, hold, sell: Premier Investments, New Hope, Xero shares

We review three fresh buy, hold, and sell calls from expert market analysts.

Read more »

Happy businessman fist pumping while looking at a tablet.
Broker Notes

Up 120%, is it too late to buy Codan shares?

Bell Potter thinks this high-flying stock could keep rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

This ASX biotech could nearly triple in value Bell Potter says

A big development in the US is good news for this company.

Read more »